2026 ASCO Highlights Webinar

June 9, 2026

10:00-11:00am MDT

Webinar Description

Join us for an exclusive webinar that delves into the most groundbreaking studies and updates presented at the 2026 American Society of Clinical Oncology (ASCO) meeting. This webinar will focus on pivotal advancements in the treatment and management of lung cancer, providing valuable insights for healthcare professionals involved in lung cancer care.

Faculty and Speakers

Rebecca Heist, MD, MPH

Medical Oncologist, Massachusetts General Hospital

Moderator

Kaushal Parikh, MBBS

Medical Oncologist, Mayo Clinic

Moderator

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

Physicians

The International Association for the Study of Lung Cancer designates the live and enduring activity for a maximum of 1 AMA PRA Category 1 Credits™ . Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Associates
The National Commission on Certification of Physician Associates (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

It is the CME Activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation.

Check Out Upcoming Events

Access Past IASLC Webinars

Discover Upcoming IASLC Conferences

Connect with Peers Around the World

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.